Clinical Trial Update: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of PF-06804103 in HER2-positive and HER2-negative solid tumors (part 2 negative) in breast cancer; the trial (NCT03284723) was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PF-06804103

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2024-09-03